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Objective: Pregnancy and the postpartum (PP) period are associatedwith profound changes of the
immunesystem,which largely influence theclinical activityofautoimmunediseases. Theaimof this
study was to evaluate the effect of pregnancy and/or the PP period in driving a clinical relapse of
hyperthyroidism in patients with Graves’ disease (GD) who are in remission after antithyroid drug
(ATD) treatment. Datawere retrospectively collected from150 female patientswithGD,whowere
assigned to two groups according to the occurrence of a successful pregnancy after ATD
withdrawal.
Results: Relapsing Graves’ hyperthyroidism was observed in 70 of 125 patients in group I (no
pregnancy after ATD withdrawal) (56.0%) and 21 of 25 patients in group II (pregnancy after ATD
withdrawal) (84.0%) (P  0.05). Logistic regression analysis (dependent variable: relapse/nonre-
lapse; covariates: age, positive family history for autoimmune thyroid disease, duration of treat-
ment with ATD, number pregnancies at diagnosis, number of pregnancies after ATD withdrawal)
showed a significant effect only for the number of pregnancies after ATD withdrawal [4.257
(1.315–13.782)]. The effect was ascribed to the PP period rather than to pregnancy itself because
in 20 of 21 patients of group II (95.2%), the relapse of Graves’ hyperthyroidism occurred between
4 and 8 months after delivery.
Conclusions: The PP period is significantly associated with a relapse of hyperthyroidism in GD
patients being in remissionafterATD.We therefore recommend thatpatientswithGD in remission
after a course of ATD should have their thyroid function tested at 3 and 6 months after delivery.
(J Clin Endocrinol Metab 93: 3985–3988, 2008)
Graves’ disease (GD) is aggravated in early pregnancy, ame-liorates in the second half of gestation, and often reexac-
erbates in thepostpartum (PP) (1–3). Studies aimedat identifying
possible predictive factors for the PP aggravation of Graves’ hy-
perthyroidism showed that, among all GD patients undergoing
pregnancy, those experiencing a thyrotoxic phase in early preg-
nancy are at higher risk of developing severe hyperthyroidism in
the PP period (2). The medical treatment of Graves’ hyperthy-
roidism with thionamides (methimazole or propylthiouracile),
although effective in reestablishing euthyroidism, is associated
with a high rate of relapsing hyperthyroidism once these drugs
are discontinued (4, 5). In the majority of cases, relapses of hy-
perthyroidism occur between 6 months and 2 yr after discon-
tinuation of antithyroid drugs (ATD), but long-term relapses
may also occur after this period (4). Despite these discouraging
results, a consistent percentage (nearly 30%) of Graves’ patients
will enter a prolonged remission after ATD. Thus, medical treat-
ment still remains a valid therapeutic option in GD (1, 3).
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Normalpregnancy is associatedwithprofoundchangesof the
immune system, which largely influence the clinical activity of
autoimmune diseases (6–8). It is known that during pregnancy
a shift to a type 2 polarized cytokine profile occurs, which min-
imizes the maternal cell-mediated immune response against the
fetus (7). These changes allow maintaining the fetal-maternal
allograft, which is not rejected despite diverse paternal histo-
compatibility antigens (9). These pregnancy-induced changes re-
sult in a down-regulation of the Th1-mediated effector arms of
the immune system, which sustain the clinical remission ob-
served during pregnancy inmost patients with autoimmune thy-
roid disease (AITD) (7). On the other hand, the PP period is
characterized by a rebound reaction which, accounts for the ag-
gravation of AITD during the puerperium (10, 11). The PP-re-
bound immunity, which is characterized by a Th2 to Th1 return
shift, is considered to be responsible for the reactivation of not
only AITD but also other Th1-dependent autoimmune disease,
such as rheumatoid arthritis (12–15).
The role played by the PP-rebound of immunity, on both the
de novo occurrence of GD and the clinical course of GD in pa-
tients treated with ATD, have been previously investigated (16–
18). However, little is known on the effect played by pregnancy
and the PP period in patients with GD, who are in remission
after ATD.
The aim of this study was to evaluate the effect of pregnancy
and/or the PP period in driving a clinical relapse of hyperthy-
roidism in GD patients who were in remission after ATD.
Patients and Methods
Patients
The study group encompassed female patients who received a diag-
nosis of GD in our outpatient clinics between 2000 and 2005. Inclusion
criteria were: 1) female patients experiencing GD in their child-bearing
age; 2) availability of a reproductive history, including the number of
full-term pregnancies before the diagnosis of GD and throughout the
study span; 3) completion of a full course (at least 12 months) of me-
thimazole (MMI) treatment with restoration of euthyroidism, as as-
sessed by normal serum levels of free T4, free T3, and TSH; and 4) re-
mission of Graves’ hyperthyroidism, as assessed by clinical and
biochemical euthyroidism, lasting for at least 6 months after withdraw-
ing ATD.
A total number of 214 GD patients fulfilled the above criteria. All
patients were Caucasians. Their median age and range was 32 (19–43)
yr. Hyperthyroid GD and relapsing Graves’ hyperthyroidism were di-
agnosed by measuring the serum concentrations of free T4, free T3, and
TSHand searching for circulating thyroid antibodies (antithyroglobulin,
antithyroperoxidase, andanti-TSHreceptors antibodies).Anultrasound
scanof the thyroidglandwasperformed inall patients andwas consistent
with a diagnosis ofGD, including evidence of an increased thyroid blood
flow. Thyroid scintiscan was performed in doubt cases to rule out de-
structive thyroiditis. The child-bearing age was defined, taking into ac-
count the age of the youngest (19 yr) and oldest (43 yr) womanwithGD,
who experienced a successful pregnancy. The PP period was defined as
1 yr after delivery. To evaluate the role of pregnancy and the PP period
in precipitating a relapse of hyperthyroidism, two groups of patients
were constituted: group I encompassed 189 patients, who did not un-
dergo pregnancy after stopping MMI treatment. Group II encompassed
25 patients, who had at least one successful pregnancy after stopping
MMI. The mean age was significantly greater (P  0.0001) in group I
(32.1 5.3 yr), compared with group II (27.3 5.8 yr). To balance the
two groups for the age factor, patients in group I were stratified accord-
ing to their age at diagnosis and, starting from the oldest one, they were
excluded from the study until a nonsignificant differencewas reached for
the mean age between patients in groups I and II. After this procedure,
the final group I encompassed 125 patients with GD who did not have
a pregnancy after stopping MMI treatment. GD patients were treated
with ATD for a median time of 17.5 (12–120) months. The length of the
surveillance period, including patients who experienced a relapse of hy-
perthyroidism, was 16 (6–360) months.
Informed consent, concerning the future use of clinical-pathological
data for research purposes, is routinely obtained from all patients at-
tending our clinics. This study was in accordance with the Institution
Ethics Committee on human experimentation.
Statistical analysis
Statistical analysis was performed using SPSS software (SPSS, Inc.,
Evanston, IL). Between-group comparisonswere performed bymeans of
Student t test for unpaired data and Mann-Whitney U test according to
a normal or a nonparametric distribution of the variable tested. Fre-
quencies among groups were compared by 2 test with Fisher’s correc-
tion, when appropriate. To test the effects of different variables inde-
pendently of a covariate, binary logistic regression analysis was used and
partial correlation coefficients were computed. P 0.05was considered
statistically significant.
Results
Clinical data of patients with GD, subdivided into two groups
according to the occurrence of a pregnancy during the follow-up
period, are shown in Table 1. In detail, the two groups did not
significantly differ in age, duration of treatment withMMI, and
total follow-up time. A significantly shorter time to relapse after
ATD withdrawal characterized women in group I.
As shown in Fig. 1, a statistically significant difference for the
relapse rate between patients in groups I and II was observed.
Indeed, a relapse ofGraves’ hyperthyroidismwas observed in 70
of 125 patients in group I (56.0%) and 21 of 25 patients in group
II (84.0%; P  0.05).
To further evaluate the effect of pregnancy in precipitating a
relapse of hyperthyroidism in GD patients being euthyroid after
ATD,multiple regression analysiswas used.A logistic regression
model was constructed by entering the relapse/nonrelapse as the
dependent dichotomic variable,whereas age, positive family his-
tory forAITD, durationof treatmentwithATD,number of preg-
nancies at diagnosis, andnumber of pregnancies afterATDwith-
drawal were entered as covariates. The results shown in Table 2
TABLE 1. Clinical data of GD patients according to the
occurrence of a pregnancy after ATD withdrawal
Group I Group II P value
Number of cases 125 25
Age (yr) 29 (19–35) 27 (21–40) NS
Duration of MMI
treatment (months)
18 (12–120) 16 (12–36) NS
Total follow-up (months) 16 (6–360) 19 (12–62) NS
Time to relapse after MMI
withdrawal (months)
14 (6–144) 19 (12–62) <0.0001
Time to relapse after
delivery (months)
6 (4–24)
Significant variables are in bold characters. NS, Not significant.
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indicate that only the number of pregnancies after ATD with-
drawal was significantly related to the occurrence of relapsing
hyperthyroidism. The specificity of this finding was confirmed
by the lack of any significant effect of the number of pregnancies
at the first diagnosis ofGD.Todiscriminate the roleofpregnancy
and the PP period as a risk factor for relapsing hyperthyroidism,
the timing of the relapse was further evaluated in patients of
group II. None of these patients experienced a relapse of hyper-
thyroidism during gestation. In 20 of 21 patients (95.2%), a
relapse of Graves’ hyperthyroidism occurred in the PP period
(between4and8monthsafterdelivery). Inonlyoneof21women
(4.8%), relapsing hyperthyroidism occurred after the PP period
(24 months after delivery). In only four of 59 patients who re-
mained in remission throughout the study span (6.8%), a preg-
nancy was recorded after MMI withdrawal.
Discussion
In our series of female patients with GD, the overall relapse rate
of hyperthyroidism after ATD treatment was 60.1%. A signifi-
cantly higher rate of relapsing hyperthyroidism was found in
patients who underwent a pregnancy after stopping ATD, as
opposed to patients who did not become pregnant. It is impor-
tant to note that in none of these patients, relapsing hyperthy-
roidism occurred during the first trimester of gestation. By con-
trast, in more than 95% of women who became pregnant after
ATD withdrawal and experienced a relapse of GD, hyperthy-
roidism developed in the PP period. Furthermore, no significant
association between the number of successful pregnancies at di-
agnosis of GD and the occurrence of relapsing hyperthyroidism
after ATD was found by multiple regression analysis. Taken
together, these findings indicate that the PP period, rather than
pregnancy itself, plays a major role in promoting a relapse of
hyperthyroidism in GD patients being in remission after ATD
treatment.
The fact that the PP period, rather than pregnancy itself, fa-
vors the relapse ofGraves’ hyperthyroidismmakes sense accord-
ing to our current knowledge of the changes in the immune sys-
tem associated with the PP period, which have been described in
the introductory text.
The design of the current study has some limitations because
it was a retrospective one, whereas a prospective longitudinal
study would be more appropriate for assessing the impact of
pregnancy on the relapse of Graves’ hyperthyroidism in patients
successfully treated by ATD. In the current study, the influence
of age at diagnosis of GD, which was previously reported to be
negatively related to a worse outcome after ATD treatment (19,
20), was tested using a multivariate logistic regression model.
This analysis showed a nonsignificant influence of the age factor
on relapsing Graves’ hyperthyroidism. However, a case-control
study with an age-matching criterion between patients with and
without a successful pregnancy after ATDwithdrawal would be
helpful to further rule out the effect of age. Thyroid volume,
serum levels of free thyroid hormones, and titers of anti-TSH
receptor antibodies, previously reported to influence the rate of
successful ATD treatment (5, 19), were not taken into account in
the present study.
Two clinical recommendations stem from our findings. First,
thyroid function should be carefully monitored in female pa-
tients with GD who undergo a pregnancy while being in remis-
sion after ATD treatment. This would be in line with the most
recently published guidelines on the treatment of thyroid dys-
function in pregnancy, which suggest evaluating thyroid func-
tion at 3 and 6 months after delivery in those women who are at
risk for postpartum thyroiditis (2). On the basis of our results, it
seems reasonable to behave similarly in Graves’ patients by eval-
uating serum thyroid function parameters and anti-TSH recep-
tors antibodies at 3 and 6 months after delivery. Second, defin-
itive treatment with thyroidectomy or radioiodine should be
strongly considered in female patients with GD who plan to
become pregnant in the following years.
In conclusion, these results indicate that the PP period is sig-
nificantly associated with a relapse of hyperthyroidism in GD
patients being in remission after ATD.We therefore recommend
that patients with GD in remission after a course of ATD should
have their thyroid function tested at 3 and 6 months after
delivery.
TABLE 2. Relative risks for relapsing Graves’ hyperthyroidism
after ATD withdrawal
P value
Relative
risk
95% CI
Lower Upper
Age (yr) 0.442 1.038 0.944 1.140
Positive family history for
AITD
0.187 0.606 0.289 1.274
Duration of MMI
treatment (months)
0.360 1.022 0.976 1.070
Pregnancies after ATD
withdrawal
0.016 4.257 1.315 13.782
Number of pregnancies
at diagnosis of GD
0.710 0.908 0.545 1.511
Significant variables are in bold characters. CI, Confidence interval.
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
Pregnancy after ATD
withdrawal
No pregnancy after ATD
withdrawal
Relapse
No relapse
p<0.05
FIG. 1. Relapsing Graves’ hyperthyroidism was observed in 21 of 25 patients
who had a pregnancy after ATD withdrawal (84.0%) and 70 of 125 patients
who did not become pregnant since ATD withdrawal (56.0%) (2 and Fisher’s
exact test; P  0.05).
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